A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)

NCT05585645 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
214
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Collaborators